Home » Germany's Merck to Use Cenix's RNAi Service to Screen for Drugs

Germany's Merck to Use Cenix's RNAi Service to Screen for Drugs

Sep 27, 2006
NEW YORK (GenomeWeb News) – Cenix BioScience today said German drug maker Merck will use its RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. UC Riverside Team Wins $14.9M DARPA Grant for Genetic Mosquito Control Research

  2. Cas1-Cas2 Integrase Structures Enable Bacteria to Adapt to New Viruses

  3. Researchers Design, Construct Genome-Wide Sequence-Verified Arrayed CRISPR Library

  4. Christiana Care, NovellusDx Ink Licensing Deal for Gene-Editing Tech

  5. Bio-Rad Laboratories Aims to Create Genome Editing Tools Pipeline, Starting With ddPCR

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.